JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AstraZeneca PLC ADR

Închisă

73.59 -1.31

Rezumat

Modificarea prețului

24h

Curent

Minim

73.52

Maxim

73.74

Indicatori cheie

By Trading Economics

Venit

-923M

2.5B

Vânzări

1B

15B

P/E

Medie Sector

27.832

34.393

Randament dividend

2.12

Marjă de profit

16.947

Angajați

94,300

EBITDA

-18M

5B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+26.44% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.12%

2.54%

Statistici piață

By TradingEconomics

Capitalizare de piață

5.1B

231B

Deschiderea anterioară

74.9

Închiderea anterioară

73.59

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

AstraZeneca PLC ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 iul. 2025, 08:08 UTC

Câștiguri

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 iul. 2025, 06:46 UTC

Câștiguri

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

8 aug. 2025, 10:51 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1 aug. 2025, 11:10 UTC

Acțiuni populare

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 iul. 2025, 11:02 UTC

Câștiguri

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 iul. 2025, 11:02 UTC

Câștiguri

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 iul. 2025, 11:01 UTC

Câștiguri

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 iul. 2025, 11:00 UTC

Câștiguri

AstraZeneca Results: H1 and Q2 2025

29 iul. 2025, 08:00 UTC

Market Talk
Câștiguri

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 iul. 2025, 07:53 UTC

Market Talk
Câștiguri

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 iul. 2025, 07:26 UTC

Market Talk
Câștiguri

AstraZeneca Shares Look Undervalued -- Market Talk

29 iul. 2025, 06:03 UTC

Câștiguri

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 iul. 2025, 06:03 UTC

Câștiguri

AstraZeneca 2Q Total Revenue $14.46B

29 iul. 2025, 06:03 UTC

Câștiguri

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 iul. 2025, 06:03 UTC

Câștiguri

AstraZeneca 2Q Core EPS $2.17

29 iul. 2025, 06:02 UTC

Câștiguri

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 iul. 2025, 06:02 UTC

Câștiguri

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 iul. 2025, 06:02 UTC

Câștiguri

AstraZeneca Backs 2025 View

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Rev $14.46B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Adj EPS $2.17

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Net Pft $2.45B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Oper Pft $3.51B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q EPS $1.57

28 iul. 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 iul. 2025, 10:19 UTC

Market Talk

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 iul. 2025, 09:34 UTC

Acțiuni populare

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 iul. 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 iul. 2025, 09:17 UTC

Acțiuni populare

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New -2-

Comparație

Modificare preț

AstraZeneca PLC ADR Așteptări

Obiectiv de preț

By TipRanks

26.44% sus

Prognoză pe 12 luni

Medie 93 USD  26.44%

Maxim 97 USD

Minim 85 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAstraZeneca PLC ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 69.55Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.